Like Viagra, Stendra, and Levitra, Cialis (the brand name of the active ingredient tadalafil) is highly effective as a ...

Sidebar Key Issues. The introduction of inhibitors of the cyclic GMP phosphodiesterase (PDE) 5 into clinical urology is mainly the result of the characterization of the physiology of nonvascular ...

Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence. Ann Surg Oncol. 2016;23(5):1760-1767. Chung JW, Kim JW, Ha YS ...

Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has become a first-line therapy for diabetic patients with erectile dysfunction (ED). The efficacy in this subgroup, based on the Global ...

Rates of Raynaud phenomenon medication initiation are low among patients with SSc in the United States, with less than one-third receiving consistent treatment.

Okay, maybe not that much money — but as one of the safest and most effective ED medications approved by the FDA (U.S. Food ...

In this overall population, from 2000 to 2018, prescriptions for PDE5 inhibitors increased 10-fold, from 3.1 to 30.9 prescriptions per 100 persons per year.

PDE5 inhibitors show promise as a future treatment for LUTS, either in conjunction with existing therapies or as a primary treatment. To review the current literature regarding the relationship ...

Phosphodiesterase 5 (PDE5) inhibitors (eg, sildenafil, tadalafil) do not appear to reduce the risk of Alzheimer disease and related dementias, according to a National Institutes of Health (NIH) study.

There is a class of drugs called “Phosphodiesterase-5 inhibitors” (PDE5 inhibitors.) Such drugs in this class are known as sildenafil, vardenafil, tadalafil, and avanafil.1 These drugs all work by ...

Patients with pulmonary arterial hypertension at intermediate risk who switched from phosphodiesterase type 5 inhibitors to riociguat experienced clinical improvement at 24 weeks, according to ...

Melanoma Risk with PDE5 Inhibitors Likely Due to Sun, Not Side Effect A summary estimate demonstrated a higher risk of melanoma among PDE5i users (relative risk [RR] 1.11, 95% CI: 1.02–1.22).